Laser Interstitial Thermotherapy (LITT) Combined with Checkpoint Inhibitor for Recurrent GBM (RGBM)
1-800-641-2422
Phase I/II Study of Laser Interstitial Thermotherapy (LITT) combined with checkpoint inhibitor for recurrent Glioblastoma (rGBM)
- Sex: Any
- Age: Adult (18 - 64), Older Adult (65+)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase I
- Conditions Being Studied: Cancer - Brain and Nervous System
Study Purpose
The purpose of this study is to test the side effects and efficacy of using Laser Interstitial Thermotherapy (LITT) combined with the Pembrolizumab. LITT is a minimally invasive surgical technique that uses a laser to heat brain tumors. Pembrolizumab is an investigational (experimental) drug that works by helping participants' immune system work correctly to detect and fight cancer cells. Pembrolizumab is experimental because it is not approved by the Food and Drug Administration (FDA), for this use, though it is approved to treat other cancers.
Who Can Participate
Patients 18 years and older with a diagnosis of glioblastoma or gliosarcoma may be eligible for this study.
Locations
UH Seidman Cancer Center
11100 Euclid Avenue
Cleveland OH, 44106
- UH IRB: 08-17-09C
- StudyID: CASE3316
- ClinicalTrials.gov: NCT03277638
1-800-641-2422
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422